Amber Galownia
Family · Mansfield, OHNPI 1629629753
Payments from drug & device makers
Across 221 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- AbbVie$815
- Indivior Inc.$303
- Johnson & Johnson$278
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$211
- Braeburn Inc.$200
- plus $1K from 26 others
What the payments were for
- Consulting fees$1,43024%
- Travel & lodging$2584%
- Food & beverage$4,31072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 52 | $2,697 |
| AbbVie | 52 | $815 |
| Indivior Inc. | 10 | $303 |
| Johnson & Johnson(2 entities) | 7 | $278 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $211 |
| Braeburn Inc. | 11 | $200 |
| Bayer | 9 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $158 |
| Corcept Therapeutics | 8 | $154 |
| Lilly USA, LLC | 9 | $147 |
| Novartis | 5 | $116 |
| Alkermes, Inc. | 5 | $91 |
| Exact Sciences | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $69 |
| AstraZeneca | 4 | $65 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Edwards Lifesciences | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Almirall LLC | 1 | $36 |
| Organon | 1 | $34 |
| Pfizer | 2 | $33 |
| Neurelis, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $23 |
| Merck | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Viiv Healthcare Company | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,998 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 68 | $63,739 |
| JardianceEmpagliflozin | 58 | $62,177 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $35,456 |
| TrulicityDulaglutide | 25 | $35,147 |
| OzempicSemaglutide | 25 | $24,778 |
| LinzessLinaclotide | 16 | $15,498 |
| MounjaroTirzepatide | 14 | $15,159 |
| EliquisApixaban | 19 | $14,406 |
| Spiriva HandihalerTiotropium Bromide | 18 | $13,628 |
| Spiriva RespimatTiotropium Bromide | 15 | $12,643 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,956 |
| XareltoRivaroxaban | 14 | $8,084 |
| FarxigaDapagliflozin Propanediol | 11 | $7,995 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,840 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Dulera | $23 | $68,88983 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $147 | $50,30639 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $14 | $49,08381 claims |
| Novo NordiskOzempic | $17 | $24,77825 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $65 | $24,20046 claims |
| AbbVieLinzess | $815 | $15,49816 claims |
| PfizerEliquis | $33 | $14,40619 claims |
| Johnson & JohnsonXarelto | $278 | $8,08414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Mansfield
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.